Please Wait

Applying Filters...

List of JP reference standards related to Prostavasin

Prostavasin

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

18 API Suppliers, 8 USDMF, 2 CEP/COS, 1 JDMF, 2 KDMF, 13 NDC API, 12 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

FINISHED DOSAGE FORMULATIONS

77 FDF Dossiers, 23 FDA Orange Book, 41 Europe, 3 Canada, 2 Australia, 2 South Africa, 6 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - 0.005MG/VIAL, INJECTABLE;INJECTION - 0.01MG/VIAL, INJECTABLE;INJECTION - 0.02MG/VIAL, INJECTABLE;INJECTION - 0.04MG/VIAL

RELATED EXCIPIENT COMPANIES

1 Nanjing Well Pharmaceutical, 4 Actylis, 2 BASF, 1 Finar, 3 Kerry, 1 Roquette

EXCIPIENTS BY APPLICATIONS

4 Parenteral, 3 Co-Processed Excipients, 2 Topical, 2 Granulation, 2 Direct Compression, 1 Solubilizers, 1 Controlled & Modified Release, 1 Fillers, Diluents & Binders, 1 Coating Systems & Additives

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 31 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 30 Finished Drug Prices

MARKET PLACE

24 APIs, 7 FDF Dossiers

PATENTS & EXCLUSIVITIES

14 Health Canada Patents

14 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 1 USP, 4 JP, 1 Others

$ Xls

Filters

Filters

FILTER :

filter Reference Standard Reset all filters

4 All

01 4Alprostadil

filter Monograph in Japanese Pharmacopoeia Reset all filters

Product Main Page

01

Japanese Pharmacopoeia

Japan

AAPS 2024

Not Confirmed

02

Japanese Pharmacopoeia

Japan

AAPS 2024

Not Confirmed

03

Japanese Pharmacopoeia

Japan

AAPS 2024

Not Confirmed

04

Japanese Pharmacopoeia

Japan

AAPS 2024

Not Confirmed

Contact us
to update this info